01877 JUNSHI BIO
- 11.600
- -0.160-1.36%
JUNSHI BIO News
Junshi Biotech (688180.SH): A total of 781,500 shares have been repurchased
Gelonghui, April 30, 丨 Junshi Biotech (688180.SH) announced that as of April 30, 2024, the company had repurchased 781,486 shares through centralized bidding transactions, accounting for 0.0793% of the company's total share capital. The highest repurchase transaction price was RMB 41.69 per share, the lowest price was RMB 29.21 yuan/share, and the total amount of capital paid was RMB 29,883,225.58 (excluding transaction fees such as stamp duty and transaction fees).
Express News | Science and Technology Innovation Board Evaluation: Low-altitude economy, semiconductor sector falls across the board, biological products sector rises
Junshi Biotech (688180): Tuoyi's sales revenue increased 57% year-on-year in Q1, and the expansion of indications achieved remarkable results
Incident: Recently, the company released its report for the first quarter of 2024. The company's revenue for the first quarter of 2024 was 381 million yuan (+49.24% year over year), and R&D expenses were 276 million yuan (year-on-year - 47.64 million yuan)
Changes in Hong Kong stocks | Junshi Biotech (01877) rose more than 6% in the afternoon, Q1 revenue increased 49.24% year-on-year, and losses narrowed by 47.92%
The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 6% in the afternoon. As of press release, it had risen 4.24% to HK$11.3, with a turnover of HK$14.146,600. According to the news, Junshi Biotech announced its results for the first quarter of 2024, with operating income of about 381 million yuan, an increase of 49.24%; net loss attributable to shareholders of listed companies was about 283 million yuan, a year-on-year narrowing of 47.92%; and a basic loss of 0.29 yuan per share. During the reporting period, the increase in the company's revenue was mainly due to the increase in sales revenue of commercial drugs. Among them, the core product, treprilizumab injection (
Selected announcements | BYD's net profit for the first quarter increased by nearly 11% year-on-year; CNPC's profit for the first quarter exceeded 45 billion yuan
ICBC's first quarter revenue fell nearly 3% year on year; Vanke Enterprise's first quarter revenue fell by more than 10% year on year.
Junshi Biotech (688180.SH) reported first-quarter results with a net loss of 283 million yuan
Junshi Biotech (688180.SH) released its report for the first quarter of 2024, with revenue of 381 million yuan, an increase of 49.24% over the previous year. Net loss attributable to shareholders of listed companies was 283 million yuan. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of $307 million. Basic earnings per share - $0.29.
君實生物：海外監管公告 - 上海君實生物醫藥科技股份有限公司2024年第一季度報告
Express News | Junshi Biotech: Q1 revenue of 381 million yuan, a year-on-year increase of 49.24%
君實生物：2023年度報告
Junshi Biotech (688180): The performance of the core product, Tripley, exceeded expectations in Q1 in '24, performed brilliantly
Incident: Junshi Biotech released its first quarter report, with operating income of 380 million yuan, a year-on-year increase of 49.24%, net loss of 283 million yuan, net loss of 307 million yuan after deducting non-net loss of 307 million yuan, and basic earnings per share of -0.29 yuan. Review: Company
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab
Hong Kong's Department of Health has approved a new drug application for Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) cancer drug toripalimab, according to a Wednesday release filed with the Ho
Hong Kong stock changes丨Junshi Biotech rose more than 5%, and the application for marketing license of treprilizumab was accepted by DO
Gelonghui, April 25 | Junshi Biotech (1877.HK) rallied more than 5% and now reports HK$10.22, with a total market value of HK$10 billion. Junshi Biotech's A shares are currently up 4% to 25.79 yuan. According to the news, the company received a notice from the Drug Administration (DO) of the Hong Kong Department of Health that treprimab (product code: TAB001/JS001) combined with cisplatin/gemcitabine is used as first-line treatment for adult patients with metastatic or recurrent locally advanced nasopharyngeal cancer, and as a single agent for recurrent, unresectable, or metastatic nasopharyngeal cancer patients whose disease progresses during or after treatment containing platinum
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the
Junshi Biotech (01877) appoints Wang Zhengyu as board secretary
Zhitong Finance App News, Junshi Biotech (01877) issued an announcement. Due to career development reasons, Chen Yingge applied to resign as secretary of the company's board of directors, joint company secretary and authorized representative. The resignation took effect from the date it was delivered to the company's board of directors. After Chen Yingge's resignation, he will no longer hold any position in the company. Furthermore, after the qualification review of the nomination committee of the 3rd board of directors of the company, the company held the 30th meeting of the 3rd board of directors on April 24, 2024 to review and pass the “Proposal on Appointing the Company's Board Secretary, Joint Company Secretary and Authorized Representative”. The details are as follows: Wang Zhengyu was appointed as the secretary of the company's board of directors
Express News | Junshi Biotech: Application for marketing license of treprilizumab was accepted by the Drug Office of the Hong Kong Department of Health
Junshi Biotech (01877.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Junshi Biotech (01877.HK) issued an announcement. The board of directors hereby announces that it will hold a board meeting on April 29, 2024 (Monday) to consider and approve the Group's unaudited financial results for the three months ended March 31, 2024.
君實生物：董事會召開日期
Junshi Biotech (688180.SH): Up to now, the company has no oral antihypertensive drug research and development projects
Gelonghui, April 10 | Junshi Biotech (688180.SH) said on the investor interactive platform that up to now, the company has no oral antihypertensive drug research projects.
Changes in Hong Kong stocks | Junshi Biotech (01877.HK) rose more than 6%, and Trepri's approval for kidney cancer indications is expected to boost sales
Junshi Biotech (01877.HK) rose more than 6%. As of press release, it rose 6.65% to HK$10.58, with a turnover of HK$8.916 million.
Analysis
Price Target
No Data
